About the Event
NanoTomer is poised to launch what is arguably the broadest drug delivery platform ever developed.
NanoTomer’s patented Anti-body Drug Conjugate (ADC) targets High Endothelial Venules (HEVs) that exist only in tumor draining lymph nodes, metastatic lesions, and cancerous tumors.
This hyper precision targeting means just 1/7,000 of a traditional dose can have a greater impact on multiple cancers and immune mediated diseases like Type 1 Diabetes, Multiple Sclerosis, and more, with minimal side effects.
Join our webinar to hear the inventor of this technology, Dr. Reza Abdi and NanoTomer CEO, Jeff Bell present their pre-clinical data in preparation for an IND filing with the FDA.